Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

Pediatric Ulcerative Colitis Clinical Trial

Official title:
A Phase I/II Open-Label, Proof-of-Concept Study of Vamorolone in Children and Adolescents With Mild-Moderately Active Ulcerative Colitis

Status Withdrawn

Clinical Trial Summary

This is a Phase I/II, multi-center, open-label proof-of-concept study of vamorolone. Twenty participants with a flare of mild or moderately active Ulcerative Colitis (defined as a Pediatric Ulcerative Colitis Activity Index [PUCAI] 10-60) will be enrolled and receive vamorolone 6 mg/kg/day orally once daily for 8 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04348890
Study type	Interventional
Source	ReveraGen BioPharma, Inc.
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	September 1, 2020
Completion date	September 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05673278` - Non-Invasive Monitoring Through Bowel Ultrasound in Paediatric Inflammatory Bowel Disease Study
Completed	`NCT05591976` - Exercise Training in Youth With Inflammatory Bowel Disease	N/A
Recruiting	`NCT03827109` - Peer Mentoring to Improve Self-management in Youth With IBD	N/A
Completed	`NCT01585155` - Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis	Phase 3
Terminated	`NCT02694042` - Mission is Remission®: How Can a Disease Self-management Website Change Care?	N/A